Clinical trial
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant…
NCT00006243 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006243 |
|---|---|
| Title | Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma |
| Official title | Melanoma Vaccines: Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and Gp-100) as Immune Targets |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Biological, Other |
| Interventions | tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen, incomplete Freund's adjuvant, sargramostim, laboratory biomarker analysis |
| Enrollment | 30 |
| Start date | Oct 1, 2000 |
| Primary completion | May 1, 2006 |
| First posted | May 22, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: